ТАКРОЛИМУС ПРИ ТРАНСПЛАНТАЦИИ ПОЧКИ. СООБЩЕНИЕ II

такролимус, почечная недостаточность, трансплантация почки

1. Japanese FK-506 Study Group. Japanese study of FK-506 on kidney transplantation: Results of an early phase II study. Transplant Proc 1991; 23: 3071-3074

2. Japanese FK-506 Study Group. Japanese study of FK-506 on kidney transplantation: Results of late phase II study. Transplant Proc 1993; 25: 649-654

3. Shapiro R, Jordan M, Scantlebury VP et al. FK-506 in clinical kidney transplantation. Transplant Proc 1991; 23: 3056-3067

4. Shapiro R, Jordan ML, Scantlebury VP et al. Randomized trial of FK-506 / prednisolone vs FK-506 / azathioprine / prednisone after renal transplantation: Preliminary report. Trans-plant Proc 1993; 25: 669-672

5. Vincenti F, Laskow DA, Neylan JF et al. One-year follow-up of an open-label trial of FK-506 for primary kidney transplantation. Transplantation 1996; 61: 1576-1581

6. Schleibner S, Krauss M, Wagner K et al. FK-506 versus cyclosporine in the prevention of renal allograft rejection – European pilot study: six-week results. Transplant Int 1995; 8: 86-90

7. Mayer AD, Dmitrewski J, Squifflet JP et al. Multicenter ran-domized trial comparing tacrolimus (FK-506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436-443

8. Pirsch JD, Miller J, Deierhoi MH et al. for the FK-506 Kidney Transplant Study Group. A comparison of tacrolimus (FK-506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977-983

9. Mayer AD. Four-year fol-low-up of the European tacrolimus multicenter renal study. Transplant Proc 1999; 31[Suppl. 7A]: 27S-28S

10. Jensik SC. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. Transplant Proc 1998; 30: 1216-1218

11. Hricik DE, O’Toole MA, Schulak JA, Herson J. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4: 1300-1305

12. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-1917

13. Pascual J, Quereda C, Zamora J, Hernandez D. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004; 78: 1548-1556

14. Wlodarczyk Z, Walaszewski J, Perner F et al. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients. Ann Transplant 2002; 7: 28-31

15. Wlodarczyk Z, Walaszewski J, Perner F et al. Steroid withdrawal at three months after kidney transplantation: a comparison of two tacrolimus-based regimens. Transplant Int 2005; 18: 157-162

16. Vanrenterghem Y, van Hooff JP, Squifflet JP et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 2005; 5: 87-95

17. Pascual J, van Hooff JP, Salmela K et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006; 82: 55-61

18. Rostaing L, Cantarovich D, Mourad G et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807-814

19. Vitko S, Klinger M, Salmela K et al. Two corticosteroid-free regimens – tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil – in comparison with a standard triple regimen in renal transplantation: results of the atlas study. Transplantation 2005; 80: 1734-1741

20. Kramer BK, Kruger B, Mack M et al. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens. Transplant Proc 2005; 37: 1789-1791

21. Ekberg H, Tedesco-Silva H, Demirbas A et al. SYMPHONY: Comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. Am J Transplant 2006; 6 [Suppl 2]: 83 (abstract)

22. Vitko S, Wlodarczyk Z, Kylloenen L et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study. Am J Transplant 2006; 6: 531-538

23. Dudley CRK for the European Tacrolimus Renal Rejection Study Group. Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients. 2001; 33: 1034-1035

24. Kliem V, Radermacher J, Hiss M et al. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation. Transplant Proc 1999; 31 [Suppl. 7A]: 37S–40S

25. Jordan ML, Shapiro R, Vivas et al. Outcome of tacrolimus conversion therapy for renal allograft rejection: 5-year follow-up. Transplant Proc 1999; 31 [Suppl. 7A]: 81S–83S

26. Woodle ES, Thistlethwaite JR, Gordon JH et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection: a report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation 1996; 62: 594-599

27. Almond PS, Matas A, Gillingham K et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-756

28. Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590

29. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991; 251: 233-287

30. Pretagostini R, Rossi M, Colonnello M et al. Conversion from ciclosporin to tacrolimus in chronic allograft nephropathy. Transplant Proc 2001; 33: 1025-1026

31. Meier M, Nitschke M, Weidtmann B et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. Transplantation 2006; 81: 1035-40

32. Waid T for the CRAF Study Group. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure. Clin Transplant 2005; 19: 573–580

33. Morris-Stiff GJ, Baboolal K, Dunstan F, Jurewicz WA. Conversion from cyclosporin (Neoral) to tacrolimus (Prograf) in renal allograft recipients with chronic graft nephropathy: Results of an observational study. Transplant Int 1999; 12: 288-292

34. Shapiro R, Scantlebury VP, Jordan ML et al. FK-506 in pediatric kidney transplantation – Primary and rescue experience. Pediatr Nephrol 1995; 9: 43-48

35. Latta K, Offner G, Oldhafer K et al. Tacrolimus nach Nierentransplantation bei Kindern. Transplantationsmedizin 1994; [Suppl]: 19 (abstract)

36. Corey HE, Tellis V, Schechner R, Greenstein SM. Improved renal allograft survival in children treated with FK 506 (tacrolimus) rescue therapy. Pediatr Nephrol 1996; 10: 720-722

37. Flynn JT, Bunchman TE, Sherbotie JR. Indications, results, and complications of tacrolimus conversion in pediatric renal transplantation. Pediatr Transplant 2001; 5: 439-446

38. Shapiro R, Scantlebury VP, Jordan ML et al. FK506 in pediatric kidney transplantation – primary and rescue experience. Pediatr Nephrol 1995; 9: 43-48

39. Franz M, Regele H, Schmaldienst S et al. Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? Transplantation 1998; 66: 1258-1262

40. Morris-Stiff G, Talbot D, Balaji V et al. Conversion of renal transplant recipients from cyclosporin (Neoral) to tacrolimus (Prograf) for haemolytic uraemic syndrome. Transplant Int 1998; 11 [Suppl. 1]: S98-S99

41. Zarifian A, Meleg-Smith S, O’Donovan R et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999; 55: 2457-2466

42. Lin CC, King KL, Chao YW et al. Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol 2003; 16: 580-585

43. Furlong T, Storb R, Anasetti C et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplantation 2000; 26: 985-991

44. Busque S, Demers P, St-Louis G et al. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. Transplant Proc 1998; 30: 1247-1248

45. Kohnle M, Lutkes P, Zimmermann U et al. Conversion from cyclosporine to tacrolimus in renal transplant recipients with gum hyperplasia. Transplant Proc 1999; 31 [Suppl. 7A]: 44S-45S

46. Margreiter R, Pohanka E, Sparacino V et al. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing cyclosporin-related side-effects. Transplant Int 2005; 18: 816-823

47. Plosker GL, Foster RH. Tacrolimus. A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59: 323-329

48. Artz MA, Boots JMM, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4: 937-945

49. McCune TR, Thacker LR, Peters TG et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation. Transplantation 1998; 65: 87-92

50. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12: 368-373